Online inquiry

IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15189MR)

This product GTTS-WQ15189MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Crohn's disease (CD), Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15189MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2947MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ4854MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ14192MR IVTScrip™ mRNA-Anti-ANGPT2, REGN-910(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-910
GTTS-WQ15041MR IVTScrip™ mRNA-Anti-CD47, SRF-231(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SRF-231
GTTS-WQ11400MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-575
GTTS-WQ8520MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Hu3F8
GTTS-WQ64MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ3606MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW